Mark Dowling Email & Phone Number

Paris, France, Fr

Lexington, Massachusetts, Us

Lexington, Massachusetts, Us

Basel, Baselstadt, Ch

Basel, Baselstadt, Ch

Basel, Baselstadt, Ch

Basel, Baselstadt, Ch

• Established the Enzymology group and made key hiring and procurement decisions, directly responsible for scientific direction and long-term strategic plan of the group.• Responsible for the daily management, motivation and scientific direction of a team of thirteen research associates which provides in vitro compound profiling to drug discovery projects• Member of the Molecular Pharmacology (Compound profiling Unit) Leadership team• Project Team Head for 2 global drug discovery projects (GPCR and enzyme target). Key Achievements:The newly formed enzymology group encompass Biochemical, Biophysics (SPR, ITC, DSF) and Analytical (LC-MS/MS) methodologies to provide innovative and contemporary ligand-enzyme compound profiling. Group has extensive expertise in both compound profiling (IC50, Ki determination) and more complex mechanism of action studies (binding site determination, reversibility, tight-binding analysis). In the first year the group has provided expertise to support both target validation and clinical compound selection. Group has expertise in kinetics assays which has aided the selection of drug candidates on dissociation rates (koff) in addition to affinity parameters. I have also proposed and developed a series of novel, innovative PK:PD assays which has enabled rapid compound progression. Established an enzymology and kinetics network across NIBR to enable effective knowledge exchange and to challenge existing experimental paradigms.

Basel, Baselstadt, Ch

• Directly responsible for the daily management and development of a team of six research associates reporting to the Head of Receptor Pharmacology.• Accountable for medium-high throughput in vitro pharmacology assays (running, reporting and development) for multiple GPCR drug discovery programmes. • Provided expertise to Respiratory Disease Area on GPCR pharmacology and lipid activated (Sphingosie-1 phosphate and Lysophosphatidic Acid) receptors and enzymes.Key Achievements:Group developed several novel assays/methodologies to study the mechanism of action of ligands binding Sphingosine-1 phosphate activated receptors directly leading to the identification of a series of allosteric binders. The group was also responsible for exploring the anti-fibrotic potential of a number of targets using cell based assays (Human Lung Fibroblasts). I also secured internal funding for a post-doc dedicated to research into lung slices as a model system of fibrosis, which has supported a numerous target validation efforts.

Basel, Baselstadt, Ch

• Head of High-Throughput Screening Laboratory, leading a team of 3 research technicians which delivered four drug-finding compound screens in 2007.• Designing, optimising and validating of multiple High Through-put Screening assays.. • Responsible for the establishment of the Allosteric Modulation Platform which provided quantitative pharmacological information on the mechanism of action of potential clinical compounds.Key Achievements:Designed functional and binding assays to identify allosteric compounds and provide Medicinal Chemists with quantitative information to further optimise compounds. Established the Addex ‘Allosteric flow-chart’ which was based on complex receptor theory models, to aid all future drug development programmes understand and optimise allosteric compounds .Initiated a series of pharmacology tutorials to improve the basic scientific understanding of allosterism for all associates

Basel, Baselstadt, Ch

• Integral part of a receptor pharmacology Lab as part of assay development and compound profiling team of 8-9 scientists which provided expert opinion and support for all GPCR projects. Involved in all aspects of the quantitative assessment of ligand-receptor interactions.• Directly supervised 4 Industrial Trainee students with full responsibility for their internal and personnel project work.Key Achievements:Developed several innovative radioligand binding assays to quantify complex receptor-ligand binding interaction. In particular I developed a medium throughput assay to quantify the association and dissociation rates of non-radiolabelled ligands.